Clinical trials
Recurrence clinical trials
Below are recruiting recurrence clinical trials, each written for real people, not researchers. We’re tracking 1,384 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04962867RecruitingPhase 2
Targeting FGFR changes in advanced, hard-to-treat cancers
This Phase 2 study tests a treatment aimed at specific FGFR (a cancer-growth signal) changes found in your tumor. It may help people whose cancer has spread, cannot be removed, or has stopped responding to standard treatment.
Chuo-ku, Tokyo, JapanAges 20 years+ - NCT06006039Recruiting
Study on immune cells and Crohn's disease recurrence after surgery
This study looks at how certain immune cells relate to Crohn's disease coming back after bowel surgery. The goal is to better understand why some patients have a recurrence, which could help improve future treatments.
Toronto, OntarioAges 18 years+ - NCT05945875RecruitingPhase 1
Dual scans to find head and neck cancer spread
This early-stage study tests two different imaging (scanning) methods to better detect head and neck cancer. Your results from the scans may help doctors see where disease is before standard surgery to remove lymph nodes in the neck.
Nashville, TennesseeAges 19 years+ - NCT06204705Recruiting
App to Predict Bipolar Episodes in Veterans
This study uses a smartphone app to track your mood and daily habits and predict when a bipolar episode might be coming. The goal is to help you and your care team take action early to prevent a full episode.
Minneapolis, MinnesotaAges 18 years+ - NCT06184035RecruitingPhase 1/Phase 2
Testing a radioactive drug for advanced solid tumors
This trial tests a new radioactive drug, 177Lu-SN201, for people with advanced solid tumors that have not responded to other treatments. The goal is to see if it can shrink tumors and to find the best dose.
Adelaide, South AustraliaAges 18 years+ - NCT06186401RecruitingPhase 1
Experimental immune cell therapy for a specific type of brain cancer
This trial tests a personalized immune cell treatment for a glioblastoma brain tumor that has a specific marker called EGFRvIII. The cells are made in a lab and given by infusion, and the study aims to see if they can safely target and attack the tumor.
San Francisco, CaliforniaAges 18 years+ - NCT06193759RecruitingPhase 1
Immune cell therapy for malignant pediatric brain tumors
This trial tests a new immune therapy using your child's own specially trained white blood cells to fight brain tumors. The treatment is given directly into the fluid around the brain, and it is for children with specific types of brain cancer.
Washington D.C., District of ColumbiaAges 1–30 - NCT06197776Recruiting
Predicting treatment success for advanced nasopharyngeal cancer
This study uses advanced testing (multi-omics) to predict if combining chemoradiation with immunotherapy works better for nasopharyngeal cancer that has returned or spread. It aims to find the right treatment for each person.
Guangzhou, GuangdongAges 18–70 - NCT06201494Recruiting
Studying early symptoms of asthma in children
This study follows children and teens who are being checked for asthma for the first time. It aims to learn more about the early symptoms of asthma to improve diagnosis and treatment.
PragueAges 3–18 - NCT06193356Recruiting
Can endoscopists learn to spot scar after polyp removal?
This study tests whether endoscopists can learn to see scarring and find any remaining tissue after polyp removal. It may help improve how doctors check for cancer coming back.
GhentAges 18 years+ - NCT06157060Recruiting
Predicting liver cancer return after surgery with a blood test
This trial is for people with early-stage liver cancer who are scheduled for surgery. It uses a simple blood test to look for tiny bits of tumor DNA after treatment, which may help predict if the cancer will come back.
Foshan, GuangdongAges 18–75 - NCT06177964RecruitingPhase 2
Lerapolturev infusion for recurrent glioblastoma
This trial tests a new drug called lerapolturev (also known as PVSRIPO) for people whose glioblastoma has come back. The drug is delivered directly into the tumor during a small procedure. Researchers want to see if it can help control the tumor.
Durham, North CarolinaAges 18 years+ - NCT03418961RecruitingPhase 3
Study of heart-risk management for metastatic HER2 breast cancer
This trial follows people with metastatic HER2-positive breast cancer who are at higher risk for heart damage while on HER2-targeted therapy. Some participants are randomly assigned to different monitoring/heart-protection approaches to see what best helps keep the heart safe.
Anchorage, AlaskaAges 18 years+ - NCT06152809RecruitingPhase 1
Immune cells with venetoclax for acute myeloid leukemia
This trial tests a combination of specially prepared immune cells (CIML NK cells) and a drug called venetoclax for people with acute myeloid leukemia (AML) or a related condition. The goal is to see if this treatment can help control the leukemia and possibly prepare for a stem cell transplant.
Boston, MassachusettsAges 18 years+ - NCT06142929Recruiting
Nerve study in Dupuytren surgery
This study looks at tiny nerves in Dupuytren disease and whether removing them during surgery helps prevent the disease from coming back. It may help you understand if this surgical approach is right for you.
Leuven, Vlaams-BrabantAges 18 years+ - NCT06132178RecruitingPhase 2
Psilocybin and rTMS for hard-to-treat depression
This study tests whether a combination of psilocybin (a psychedelic substance) and transcranial magnetic stimulation (rTMS, a noninvasive brain stimulation) can help people with treatment-resistant depression. It involves daily visits to the research center for about 2 weeks.
Austin, TexasAges 22–65 - NCT06147960Recruiting
Cancer cell proteins and cervical cancer return risk
This trial looks at whether certain proteins that stop cell death (called inhibitor of apoptosis proteins) in cervical cancer tissue can help predict if the cancer will come back after treatment. It studies patients who had chemoradiation for advanced cervical cancer.
Nîmes, GardAges 18 years+ - NCT06126744RecruitingPhase 1
Study of a virus therapy for recurrent brain cancer
This trial tests a virus-based treatment called MVR-C5252 for people whose high-grade glioma or glioblastoma has come back after standard therapy. The virus is injected directly into the tumor to try to kill cancer cells and boost the immune system. The goal is to see if it is safe and if it can shrink the tumor.
New York, New YorkAges 18 years+ - NCT06114615Recruiting
Remote monitoring after heart treatment to prevent future events
This trial tests whether digital tools can help monitor patients after a stent procedure to lower the chance of another heart problem. It aims to make follow-up care easier and more effective.
Sacramento, CaliforniaAges Any age - NCT05890352RecruitingPhase 2
Add new medicines to standard treatment for returning lymphoma
This Phase 2 study tests whether adding tafasitamab, lenalidomide, tazemetostat, and zanubrutinib (along with standard lymphoma treatment) can improve outcomes in people whose large B-cell lymphoma has returned or not responded. It may help control disease more effectively and improve response duration for eligible patients.
Tucson, ArizonaAges 18 years+ - NCT06102902RecruitingPhase 1
New drug added to chemotherapy for BRAF-mutated colorectal cancer
This trial combines a new drug called ZEN003694 with two standard chemotherapy drugs (cetuximab and encorafenib) to see if it can help people with a specific type of colorectal cancer that has the BRAF V600E mutation. This mutation makes the cancer grow, and the new drug targets it, potentially making the treatment more effective.
Costa Mesa, CaliforniaAges 18 years+ - NCT06081959RecruitingPhase 3
Study of SKB264 for advanced HR+/HER2- breast cancer
This trial tests a new drug called SKB264 for people with a common type of breast cancer (HR+/HER2-) that has spread or come back and has not responded to at least one round of chemotherapy. It aims to see if this treatment can help shrink tumors or slow the disease.
Beijing, Beijing MunicipalityAges 18–75 - NCT06103864RecruitingPhase 3
Study of Dato-DXd with or without durvalumab for advanced triple-negative breast cancer
This trial is testing whether a new drug combination (Dato-DXd with or without durvalumab) works better than standard chemotherapy plus pembrolizumab for people with a certain type of advanced triple-negative breast cancer that has a protein called PD-L1. The study aims to find a more effective treatment option for this specific group.
Daphne, AlabamaAges 18 years+ - NCT06090903Recruiting
MRI Study to Understand Glioblastoma Biology Before Surgery
This study uses MRI scans to learn more about the biology of glioblastoma before and after surgery. It may help doctors understand how the tumor behaves and improve future treatments.
Los Angeles, CaliforniaAges 18 years+
Hear when a new Recurrence trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for recurrence?
- Yes. Clin2 currently lists 1,384 recruiting recurrence studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a recurrence trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a recurrence trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.